Business Context and Reporting Period
This Form 8-K was filed by Aligos Therapeutics, Inc. (ALGS) on February 4, 2026, reporting events occurring on January 29, 2026. The company is a biopharmaceutical entity incorporated in Delaware and listed on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change reported is the appointment of a new Principal Accounting Officer. Lesley Ann Calhoun continues to serve as Executive Vice President, Chief Operating Officer, and Chief Financial Officer.
Management Commentary and Personnel Updates
- Appointment: Nikhil Aneja was appointed as Principal Accounting Officer, effective January 29, 2026.
- Succession: Mr. Aneja succeeds Ms. Calhoun in the Principal Accounting Officer role, though she retains her existing executive titles.
- Background: Mr. Aneja, 49, is a Certified Public Accountant who has served as Vice President, Finance since February 2024. His prior experience includes roles at CareDx, Inc., Blade Therapeutics, Inc., and Global Blood Therapeutics, Inc.
Investor Verification Checklist
- Verify the effective date of Nikhil Aneja's appointment as Principal Accounting Officer.
- Confirm that Lesley Ann Calhoun retains her roles as COO and CFO.
- Review Mr. Aneja's prior tenure at CareDx, Blade Therapeutics, and Global Blood Therapeutics for relevant industry experience.